Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 96.01M P/E - EPS this Y -14.40% Ern Qtrly Grth -
Income -60.61M Forward P/E -152.00 EPS next Y 9.70% 50D Avg Chg -6.00%
Sales 4.8M PEG 0.02 EPS past 5Y - 200D Avg Chg 52.00%
Dividend N/A Price/Book 2.41 EPS next 5Y -25.00% 52W High Chg -23.00%
Recommedations 2.00 Quick Ratio 1.43 Shares Outstanding 79.94M 52W Low Chg 176.00%
Insider Own 8.54% ROA -38.30% Shares Float 0.99B Beta 0.93
Inst Own 1.64% ROE -189.23% Shares Shorted/Prior 591.45K/324.65K Price 1.52
Gross Margin 23.08% Profit Margin - Avg. Volume 439,077 Target Price 13.75
Oper. Margin -247.15% Earnings Date - Volume 179,098 Change -3.18%
About BioLineRx Ltd.

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BioLineRx Ltd. News
04/17/24 BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
04/10/24 BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
04/01/24 BioLineRx Announces $6 Million Registered Direct Offering
03/27/24 BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
03/27/24 BLRX: First Aphexda Sales Recognized
03/26/24 BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
03/20/24 BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
03/04/24 BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
02/28/24 BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
02/26/24 BLRX: Poster Presentations
02:12 PM 3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
02/16/24 BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
12/21/23 BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
11/21/23 BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript
11/21/23 BLRX: A Series of Fortunate Events
11/20/23 BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
11/13/23 BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
11/02/23 3 Tech Stocks That Wall Street Loves More Than Nvidia
10/31/23 BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
10/30/23 3 Top Penny Stocks to Make You a Millionaire in 5 Years
BLRX Chatroom

User Image TwongStocks Posted - 51 minutes ago

$BLRX Mozobil Q1 2024 sales in the US saw further erosion. Q2 2023 - €42m US, €69m global Q3 2023 (entry of generic plerixafor) - €27m US, €51m global Q4 2023 - €8m US, €33m global (Aphexda $200k US) Q1 2024 - €3m US, €25m global US sales for Mozobil have fallen off a cliff since the entry of generic plerixafor in July 2023. More erosion in Q1. Question is if the continued drop was due to increased market share of generics or if Aphexda was able to carve out a larger slice. EU/Rest of World sales of Mozobil have remained fairly steady. But their notes indicate that they expect generic plerixafor competition in the EU during 2024.

User Image Stockholm111 Posted - 2 hours ago

$BLRX Self awareness is everything —-> $PLX

User Image PLX_BULLS Posted - 11 hours ago

$BLRX Just about there… I think it goes below .50c eventually!

User Image bubbarayjr Posted - 12 hours ago

$BLRX Columbia University Dept. of Surgery https://letswinpc.org/research/chemotherapy-plus-immunotherapy-trial-shows-promise/

User Image Stockbull4me123 Posted - 15 hours ago

$BLRX everyday red 🤦🏻‍♂️

User Image TrendSurfer21 Posted - 18 hours ago

$BLRX long time… we still fighting PDAC? Starter.

User Image ADAMSFBAYINVESTOR Posted - 19 hours ago

$SLS you're 100% right about it. I'm very tired and hoping that whoever short all of my biotech stocks like $SLS $PSTV $BLRX got cancer but can't their treatment.

User Image Jabed206 Posted - 19 hours ago

$BLRX no reversal in sight...

User Image Hragy Posted - 20 hours ago

$BLRX bought last 13,000 shares at 0.61. now we shell wait 🥹

User Image Lstreak Posted - 20 hours ago

$BLRX Knowing the way this CEO operates he'll probably wait untill it's at an all time low to announce a reverse stock split. I wouldn't put it past him. That' why he has never taken a dime out of his own pocket to invest in this own stock. He has destroyed shareholder value over and over again in the past 10 years. A good drug but the most horrible management team.

User Image Lstreak Posted - 20 hours ago

$BLRX This is the biggest shit stain on my portfolio. CEO and most of management must be replaced!!

User Image novoiceinvestor Posted - 20 hours ago

$BLRX Those who are long in this stock please write to the IR. They don't respond, but we should create a paper trail. At least the external board members may take notice hopefully.

User Image DiaJay Posted - 20 hours ago

$BLRX Good god. I think I’ll lend my shares. Lol what a joke.

User Image ADAMSFBAYINVESTOR Posted - 21 hours ago

@johns83 Yes, I'm 100% agreed. I'm waiting for my $sls to pop big in the next couple weeks, then I will average down $BLRX

User Image ADAMSFBAYINVESTOR Posted - 21 hours ago

$BLRX, well, I wish I had more powder to average down. We saw this last year, and then stock went up to $2 from this level. This will repeat when sales are getting better and partnership EU.

User Image HK416 Posted - 21 hours ago

$BLRX Until Phil and Holly and Kevin and their loser team are replaced with honorable and competent people who take their responsibility seriously and perform, this is the next GMDA.

User Image HK416 Posted - 21 hours ago

$BLRX How about Holly and Kevin? Those here praising them non stop as if they were miracle workers. Do you see the miracle they worked for you? 200K in sales in a 90 day period for a brand NEW ONCOLOGY drug priced at 11K. LOL!!!!!! Holly, the fast talking loser and fatso Kevin probably hitting McDonalds for lunch everyday talking about how they are going to spend their stock option millions on new mansions. LOL

User Image HK416 Posted - 21 hours ago

$BLRX Oh oh, what happened? Where are the losers who kiss Phil's ass all day long? Wishing and praying for a miracle, well here you have your miracle, losers.

User Image ilikemoney247 Posted - 21 hours ago

$BLRX at this point, its almost comical….almost

User Image Rvl76 Posted - 22 hours ago

$BLRX and at least.and as financial.advice, fire phil and save 1m every year...

User Image HK416 Posted - 22 hours ago

$BLRX Well, just as predicted by some of us here, the 50 cent handle is upon us and will be reached today. Now, the question begs, do we wait for the reverse split announcement and completion to buy to reduce our average, or in the 50 cent range? Either way, even that could cause further losses if they don't ramp us sales immediately. This is what is called a nightmare scenario for investors.

User Image Rvl76 Posted - 22 hours ago

$BLRX and some believers disagree and got angry about conparison about blrx and gmda, but is simple, without sells this will be another gmda, or succesive offering and then r/s. If there are sales, not, of course...

User Image Rvl76 Posted - 22 hours ago

$BLRX i think there can't be many believers at this point . And the remaining (a very few) believers i can't understand why, lol... Me not, that's for sure. Fire Phil an bod.

User Image johns83 Posted - 22 hours ago

$BLRX Adding again today !

User Image Danaudi Posted - 22 hours ago

$BLRX the most miserable and dirty crooks in the entire world!

User Image TwongStocks Posted - 23 hours ago

$BLRX Appears that Dr. Manji will present CHEMP4METPANC in a poster session at ASCO. I assume that this is for the initial data that they released last year. Abstract submissions were due by Feb 6 & they didn't enroll the first patient in the randomized portion until Feb 28. Does not appear to be an oral presentation. This is listed under the poster sessions, Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/posters ASCO starts May 31. This poster session is scheduled June 1. Per the ASCO website, the abstracts will be embargoed until May 23 at 5pm ET.

User Image CO145 Posted - 1 day ago

$BLRX upon appeal, 180 days to comply (trade $1 or higher for 10 days) after delisting notice is sent.

User Image johns83 Posted - 1 day ago

$BLRX Nice press release would be good with an update ..

User Image Highflying Posted - 1 day ago

$BLRX day 18. they’ll most likely do a RS in the summer, then do a substantial raise. If sales are going well it might be worth buying shares a month or two after the large raise when the price has dropped further One has to be aware though that the management are crooks

User Image cubfan22 Posted - 1 day ago

$BLRX We'll likely get the 'out of compliance' warning on May 13. SP should tank further on that, but we've got the Q1 ER only a couple weeks later. Should rise into that and if sales have improved, we move back over a dollar. If sales are still under a million, we probably drop to 20 cents. MC still well below cash value.

Analyst Ratings
HC Wainwright & Co. Buy Apr 17, 24
HC Wainwright & Co. Buy Mar 26, 24
HC Wainwright & Co. Buy Feb 29, 24
HC Wainwright & Co. Buy Nov 20, 23
HC Wainwright & Co. Buy Sep 15, 23
HC Wainwright & Co. Buy Aug 31, 23
Oppenheimer Outperform May 25, 23
HC Wainwright & Co. Buy Feb 23, 21
HC Wainwright & Co. Buy Dec 16, 20